This is a preview of subscription content, log in via an institution to check access.
Notes
Direct costs (2013 values) were calculated from a US healthcare system's perspective; all costs and QALYs were discounted at an annual rate of 3%.
Reference
Park T, et al. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia. Value in Health 17: 310-9, No. 4, Jun 2014. Available from: URL: http://doi.org/10.1016/j.jval.2014.02.008
Rights and permissions
About this article
Cite this article
Which drug strategy best cost option in schizophrenia?. PharmacoEcon Outcomes News 707, 8 (2014). https://doi.org/10.1007/s40274-014-1397-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1397-7